Across
- 2. Type of hormone
- 3. Mutation in the target binding site
- 4. Probability of a positive test in a diseased individual
- 7. Connective tissue cancer
- 8. Treatment for HER2+ breast cancer
- 11. Can come after H, K or N
- 13. The disease itself
- 15. Type of allosteric inhibition
- 16. The guardian of the genome
- 17. Loss of heterozygosity
Down
- 1. Treatment before surgery
- 5. Selecting and grouping patients based on specific biomarkers
- 6. Prognostic biomarker for breast cancer
- 9. Staging system for cancer
- 10. After this a drop in mortality is often seen
- 12. Space between neuronal membranes
- 14. Cumulative binding strength of multiple non-covalent interactions